MKIs, HS-TKIs, and immunotherapy used as a single agent or in combination for the neoadjuvant treatment of patients with thyroid cancer inside the clinical trials that are still ongoing and/or actively recruiting participants
| Drug | Tumor | Study type | Recruitment status | ClinicalTrial.gov ID |
|---|---|---|---|---|
| Larotrectinib | Solid tumor with documented NTRK gene fusion rearrangement | Phase 2 | Active, not recruiting | NCT02576431 |
| Larotrectinib | Solid tumor with documented NTRK gene fusion rearrangement | Phase 2 | Active, not recruiting | NCT02637687 |
| Lenvatinib | DTC, PDTC | Phase 2 | Recruiting | NCT04321954 |
| Selpercatinib | DTC, PDTC, ATC, MTC | Phase 2 | Active, not recruiting | NCT04759911 |
| Anlotinib | DTC, PDTC, MTC | Phase 2 | Unknown status | NCT04309136 |
| Camrelizumab + Apatinib | DTC, PDTC, MTC | Phase 2 | Unknown status | NCT04612894 |
| Pembrolizumab | DTC, PDTC | Phase 2 | Not yet recruiting | NCT05852223 |
| Nivolumab + Ipilimumab | DTC, ATC, MTC | Phase 2 | Active, not recruiting | NCT03246958 |
| Cabozantinib + Nivolumab + Ipilimumab | DTC, PDTC | Phase 2 | Active, not recruiting | NCT03914300 |
MKIs: multikinase inhibitors; HS-TKIs: highly selective tyrosine kinase inhibitors; NTRK: neurotrophic tyrosine receptor kinase; DTC: differentiated thyroid cancer; PDTC: poorly differentiated thyroid cancer; ATC: anaplastic thyroid cancer; MTC: medullary thyroid cancer